Pacira BioSciences, Inc.
PCRX
$27.00
-$0.14-0.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 11.08% | -5.31% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.08% | -5.31% | |||
| Cost of Revenue | 10.03% | 25.51% | |||
| Gross Profit | 11.63% | -16.10% | |||
| SG&A Expenses | 7.10% | 9.11% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.57% | -0.29% | |||
| Operating Income | 34.55% | -29.14% | |||
| Income Before Tax | 118.38% | -479.55% | |||
| Income Tax Expenses | 105.75% | -73.95% | |||
| Earnings from Continuing Operations | 111.18% | -859.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 111.18% | -859.64% | |||
| EBIT | 34.55% | -29.14% | |||
| EBITDA | 20.32% | -15.32% | |||
| EPS Basic | 111.17% | -860.34% | |||
| Normalized Basic EPS | 34.06% | -28.80% | |||
| EPS Diluted | 110.65% | -899.90% | |||
| Normalized Diluted EPS | 26.23% | -22.07% | |||
| Average Basic Shares Outstanding | 0.08% | -0.09% | |||
| Average Diluted Shares Outstanding | 6.29% | -8.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||